The Burrill Report
Contributor since: 2009
Company: Burrill & Company
Dendreon Cuts Jobs As It Battles Weak Sales
Hyperion Therapeutics Goes Public
Dr. Reddy's And Merck Serono Partner On Biosimilars
Vertex's Cystic Fibrosis Drug Impresses Investors
Illumina Stays Independent But Drops As Roche's Offer Expires
Endocyte Scores With Merck Partnership
Roche Hints At Negotiating Room In Illumina Bid
Amgen And AstraZeneca To Collaborate On Inflammation Portfolio
Merrimack IPO Falls Out Of The Gate
Affymax's Anemia Drug Will Create Added Competition For Amgen
Roche And Illumina Duke It Out Ahead Of Annual Meeting
Acquisition Could Jump-Start Boston Scientific's Sluggish Cardiac Defibrillator Business
Dendreon Faces New Competition As J&J Impresses With Prostate Cancer Drug
Biogen And Samsung Advance Biosimilars Venture
Galapagos Scores With Abbott Deal
Vivus Soars On FDA Panel Recommendation For New Obesity Drug
Hepatitis C Remains A Hot Play
Amyris Finds Scaling Up More Difficult Than Expected
Siemens Seeks Growth In Companion Diagnostics
AstraZeneca Axes 7,300 Jobs, 12% Of Workforce
2 Life Sciences IPOs Debut Below Target
Big Biotech Fuels M&A Activity
5 Pharma Setbacks This Week
Teva Names A New CEO
Pharmacyclics Scores Big With Janssen Biotech Deal
Senators Question Pfizer's Lipitor Deals
Affymetrix Will Pay $330 Million To Acquire eBioscience
AstraZeneca Adds $100 Million To MedImmune Ventures
Regeneron Challenges Genentech's Lucentis
Merck Pays $950M To Settle Vioxx Criminal And Civil Settlement
Pfizer Cuts Lipitor Deals To Fight Generics
Geron Dumps Stem Cells For Cancer Focus